Applied Therapeutics (APLT) Director Joel S. Marcus Buys 150,000 Shares

Applied Therapeutics (NASDAQ:APLT) Director Joel S. Marcus acquired 150,000 shares of the business’s stock in a transaction on Thursday, May 16th. The stock was acquired at an average price of $10.00 per share, with a total value of $1,500,000.00. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website.

NASDAQ:APLT opened at $10.05 on Wednesday.

COPYRIGHT VIOLATION WARNING: This story was reported by Baseball Daily News and is the property of of Baseball Daily News. If you are viewing this story on another website, it was stolen and reposted in violation of international trademark & copyright laws. The legal version of this story can be accessed at

Applied Therapeutics Company Profile

Applied Therapeutics, Inc, a biopharmaceutical company, develops novel products to target cardiovascular disease, galactosemia, and diabetic complications. Its lead product candidate is AT-001 that is in phase II clinical trials for treating diabetic cardiomyopathy, as well as is in phase I clinical trials to treat diabetic peripheral neuropathy.

Read More: Green Investing

Receive News & Ratings for Applied Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Applied Therapeutics and related companies with's FREE daily email newsletter.